1. Name and Address of Reporting Person

RYAN ARTHUR F

777 OLD SAW MILL RIVER ROAD

TARRYTOWN NY 10591

2. Issuer Name and Ticker or Trading Symbol

REGENERON PHARMACEUTICALS, INC. [ REGN ]

3. Date of Earliest Transaction (Month/Day/Year)

09/01/2020

4. If Amendment, Date of Original Filed (Month/Day/Year)

09/03/2020

5. Relationship of Reporting Person(s) to Issuer

X Director

10% Owner

Officer (give title below)

Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X Form filed by One Reporting Person

Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

<table>
<thead>
<tr>
<th>1. Title of Security (Instr. 3)</th>
<th>2. Transaction Date (Month/Day/Year)</th>
<th>2A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>3. Transaction Code (Instr. 8)</th>
<th>4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)</th>
<th>6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>7. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>20 D</td>
<td>$616.74</td>
<td>28,523 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>20 D</td>
<td>$608.69(2)</td>
<td>28,503 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>10 D</td>
<td>$605.62</td>
<td>28,493 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>10 D</td>
<td>$602.33</td>
<td>28,483 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>20 D</td>
<td>$601.13(1)</td>
<td>28,463 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>2 D</td>
<td>$600.3</td>
<td>28,461 D</td>
<td>D</td>
</tr>
<tr>
<td>Common Stock</td>
<td>09/01/2020</td>
<td></td>
<td>s(1)</td>
<td>18 D</td>
<td>$591.5</td>
<td>28,443 D</td>
<td>D</td>
</tr>
</tbody>
</table>

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**

<table>
<thead>
<tr>
<th>1. Title of Derivative Security (Instr. 3)</th>
<th>2. Conversion or Exercise Price of Derivative Security</th>
<th>3. Transaction Date (Month/Day/Year)</th>
<th>3A. Deemed Execution Date, if any (Month/Day/Year)</th>
<th>4. Transaction Code (Instr. 8)</th>
<th>5. Number of Derivative Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)</th>
<th>6. Date Exercisable and Expiration Date (Month/Day/Year)</th>
<th>7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)</th>
<th>8. Price of Derivative Security (Instr. 5)</th>
<th>9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</th>
<th>10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</th>
<th>11. Nature of Indirect Beneficial Ownership (Instr. 4)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td>Code V (A) (D)</td>
<td>Date Exercisable (A) (D)</td>
<td>Amount or Number of Shares</td>
<td>Price (A) (D)</td>
<td>Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)</td>
<td>Ownership Form: Direct (D) or Indirect (I) (Instr. 4)</td>
<td>Nature of Indirect Beneficial Ownership (Instr. 4)</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Explanation of Responses:**

1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
2. Represents volume-weighted average price of sales of 20 shares of Company stock on September 1, 2020 at prices ranging from $608.43 to $608.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 1, 2020 at each separate price.
3. Represents volume-weighted average price of sales of 20 shares of Company stock on September 1, 2020 at prices ranging from $601.00 to $601.26. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on September 1, 2020 at each separate price.

//**Arthur F. Ryan 09/03/2020

Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4(b)(v).


Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.